A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: Implications for ADHD and its treatment

Brain

Volumn 136, Issue 11, 2013, Pages 3252-3270

  Del Campo, Natalia ^a,b   Fryer, Tim D ^c,d   Hong, Young T ^c,d   Smith, Rob ^c,d   Brichard, Laurent ^c,d   Acosta Cabronero, Julio ^c,d,e   Chamberlain, Samuel R ^a,b,c   Tait, Roger ^b   Izquierdo, David ^c   Regenthal, Ralf ^f   Dowson, Jonathan ^a   Suckling, John ^a,b   Baron, Jean Claude ^d,g   Aigbirhio, Franklin I ^c,d   Robbins, Trevor W ^b   Sahakian, Barbara J ^a,b,c   Müller, Ulrich ^a,b,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^f UNIVERSITY OF LEIPZIG   (Germany)

^g CENTRE HOSPITALIER SAINTE ANNE   (France)

Author keywords

Attention deficit hyperactivity disorder; Dopamine; Methylphenidate; Sustained attention

Indexed keywords

DOPAMINE; DOPAMINE AUTORECEPTOR; METHYLPHENIDATE; PLACEBO;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOPAMINE BRAIN LEVEL; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; GRAY MATTER; HUMAN; MALE; NIGRONEOSTRIATAL SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

EID: 84890489405     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awt263     Document Type: Article

References (114)

1. Aalto S, Hirvonen J, Kaasinen V, Hagelberg N, Kajander J, Nagren K, et al. The effects of d-Amphetamine on extrastriatal dopamine D2/D3 receptors: a randomized, double-blind, placebo-controlled PET study with [11C]FLB 457 in healthy subjects. Eur J Nucl Med Mol Imaging 2009; 36: 475-83.
2. Arnsten AF, Goldman-Rakic PS. Noise stress impairs prefrontal cortical cognitive function in monkeys: evidence for a hyperdopaminergic mechanism. Arch Gen Psychiatry 1998; 55: 362-8.
3. Ashburner J, Friston KJ. Unified segmentation. Neuroimage 2005; 26: 839-51.
4. Barkley RA. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 1997; 121: 65-94.
5. Benke T, Delazer M, Bartha L, Auer A. Basal ganglia lesions and the theory of fronto-subcortical loops: neuropsychological findings in two patients with left caudate lesions. Neurocase 2003; 9: 70-85.
6. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000; 157: 816-8.
7. Boileau I, Dagher A, Leyton M, Welfeld K, Booij L, Diksic M, et al. Conditioned dopamine release in humans: a positron emission tomography [11C]raclopride study with amphetamine. J Neurosci 2007; 27: 3998-4003.
8. Bradberry CW, Barrett-Larimore RL, Jatlow P, Rubino SR. Impact of selfadministered cocaine and cocaine cues on extracellular dopamine in mesolimbic and sensorimotor striatum in rhesus monkeys. J Neurosci 2000; 20: 3874-83.
9. Bullmore ET, Suckling J, Overmeyer S, Rabe-Hesketh S, Taylor E, Brammer MJ. Global, voxel, and cluster tests, by theory and permutation, for a difference between two groups of structural MR images of the brain. IEEE Trans Med Imaging 1999; 18: 32-42.
10. Bunney BS, Achajanian GK. d-Amphetamine-induced inhibition of central dopaminergic neurons: mediation by a striato-nigral feedback pathway. Science 1976; 192: 391-3.
11. Bush G, Valera EM, Seidman LJ. Functional neuroimaging of attentiondeficit/hyperactivity disorder: a review and suggested future directions. Biol Psychiatry 2005; 57: 1273-84.
12. Castells X, Ramos-Quiroga JA, Rigau D, Bosch R, Nogueira M, Vidal X, et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs 2011; 25: 157-69.
13. Challman TD, Lipsky JJ. Methylphenidate: its pharmacology and uses. Mayo Clin Proc 2000; 75: 711-21.
14. Chamberlain SR, Del Campo N, Dowson J, Muller U, Clark L, Robbins TW, et al. Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol Psychiatry 2007; 62: 977-84.
15. Clark L, Blackwell AD, Aron AR, Turner DC, Dowson J, Robbins TW, et al. Association between response inhibition and working memory in adult ADHD: a link to right frontal cortex pathology? Biol Psychiatry 2007; 61: 1395-401.
16. Clatworthy PL, Lewis SJ, Brichard L, Hong YT, Izquierdo D, Clark L, et al. Dopamine release in dissociable striatal subregions predicts the different effects of oral methylphenidate on reversal learning and spatial working memory. J Neurosci 2009; 29: 4690-6.
17. Cools R, Robbins TW. Chemistry of the adaptive mind. Philos Trans A Math Phys Eng Sci 2004; 362: 2871-88.
18. Coull JT, Frith CD, Frackowiak RS, Grasby PM. A fronto-parietal network for rapid visual information processing: a PET study of sustained attention and working memory. Neuropsychologia 1996; 34: 1085-95.
19. Crockett MJ, Clark L, Hauser MD, Robbins TW. Serotonin selectively influences moral judgment and behavior through effects on harm aversion. Proc Natl Acad Sci USA 2010; 107: 17433-8.
20. Cropley VL, Innis RB, Nathan PJ, Brown AK, Sangare JL, Lerner A, et al. Small effect of dopamine release and no effect of dopamine depletion on [18F]fallypride binding in healthy humans. Synapse 2008; 62: 399-408.
21. Daniel DG, Weinberger DR, Jones DW, Zigun JR, Coppola R, Handel S, et al. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci 1991; 11: 1907-17.
22. Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry 2011a; 69: e145-57.
23. Del Campo N, Muller U, Sahakian BJ. Neural and behavioral endophenotypes in ADHD. Curr Top Behav Neurosci 2012; 11: 65-91.
24. Del Campo N, Tait RJ, Acosta-Cabronero J, Hong YT, Izquierdo-Garcia D, Smith R, et al. Quantification of receptor-ligand binding potential in sub-striatal domains using probabilistic and template regions of interest. Neuroimage 2011b; 55: 101-12.
25. Dews PB. Studies on behavior. IV. Stimulant actions of methamphetamine. J Pharmacol Exp Ther 1958; 122: 137-47.
26. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988; 85: 5274-8.
27. Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA, et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 2001; 49: 81-96.
28. Drevets WC, Price JC, Kupfer DJ, Kinahan PE, Lopresti B, Holt D, et al. PET measures of amphetamine-induced dopamine release in ventral versus dorsal striatum. Neuropsychopharmacology 1999; 21: 694-709.
29. Elliott R, Sahakian BJ, Matthews K, Bannerjea A, Rimmer J, Robbins TW. Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology (Berl) 1997; 131: 196-206.
30. Ernst M, Zametkin AJ, Matochik JA, Jons PH, Cohen RM. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J Neurosci 1998; 18: 5901-7.
31. Ernst M, Zametkin AJ, Matochik JA, Pascualvaca D, Jons PH, Cohen RM. High midbrain [18F]DOPA accumulation in children with attention deficit hyperactivity disorder. Am J Psychiatry 1999; 156: 1209-15.
32. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-Analysis of effect sizes. J Clin Psychiatry 2010; 71: 754-63.
33. Finke K, Dodds CM, Bublak P, Regenthal R, Baumann F, Manly T, et al. Effects of modafinil and methylphenidate on visual attention capacity: a TVA-based study. Psychopharmacology (Berl) 2010; 210: 317-29.
34. Foster ER, Black KJ, Antenor-Dorsey JA, Perlmutter JS, Hershey T. Motor asymmetry and substantia nigra volume are related to spatial delayed response performance in Parkinson disease. Brain Cogn 2008; 67: 1-10.
35. Gau SS, Huang WL. Rapid visual information processing as a cognitive endophenotype of attention deficit hyperactivity disorder. Psychol Med 2013; 1-12.
36. Gibbs SE, D'Esposito M. Individual capacity differences predict working memory performance and prefrontal activity following dopamine receptor stimulation. Cogn Affect Behav Neurosci 2005; 5: 212-21.
37. Gill KE, Pierre PJ, Daunais J, Bennett AJ, Martelle S, Gage HD, et al. Chronic treatment with extended release methylphenidate does not alter dopamine systems or increase vulnerability for cocaine self-Administration: a study in nonhuman primates. Neuropsychopharmacology 2012; 37: 2555-65.
38. Gjedde A, Wong DF, Rosa-Neto P, Cumming P. Mapping neuroreceptors at work: on the definition and interpretation of binding potentials after 20 years of progress. Int Rev Neurobiol 2005; 63: 1-20.
39. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991; 41: 1-24.
40. Grace AA. Psychostimulant actions on dopamine and limbic system function: relevance to the pathophysiology and treatment of ADHD. New York: Oxford University Press; 2001.
41. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997; 6: 279-87.
42. Haber SN. The primate basal ganglia: parallel and integrative networks. J Chem Neuroanat 2003; 26: 317-30.
43. Haber SN, Fudge JL, McFarland NR. Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. J Neurosci 2000; 20: 2369-82.
44. Joel D, Weiner I. The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 2000; 96: 451-74.
45. Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. Reduced midbrain dopamine transporter binding in male adolescents with attentiondeficit/ hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry 2005; 57: 229-38.
46. Kaasinen V, Aalto S, Nagren K, Rinne JO. Expectation of caffeine induces dopaminergic responses in humans. Eur J Neurosci 2004; 19: 2352-6.
47. Kegeles LS, Abi-Dargham A, Frankle WG, Gil R, Cooper TB, Slifstein M, et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 2010; 67: 231-9.
48. Kessler RC, Adler L, Ames M, Demler O, Faraone S, Hiripi E, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med 2005; 35: 245-56.
49. Khan ZU, Mrzljak L, Gutierrez A, de la Calle A, Goldman-Rakic PS. Prominence of the dopamine D2 short isoform in dopaminergic pathways. Proc Natl Acad Sci USA 1998; 95: 7731-6.
50. Kimberg DY, D'Esposito M, Farah MJ. Effects of bromocriptine on human subjects depend on working memory capacity. Neuroreport 1997; 8: 3581-5.
51. Kinahan PE, Rogers JG. Analytic 3D image reconstruction using all detected events. IEEE Trans Nucl Sci 1989; 36: 964-8.
52. Koelega HS. Stimulant drugs and vigilance performance: a review. Psychopharmacology (Berl) 1993; 111: 1-16.
53. Kuntsi J, McLoughlin G, Asherson P. Attention deficit hyperactivity disorder. Neuromolecular Med 2006; 8: 461-84.
54. Larisch R, Meyer W, Klimke A, Kehren F, Vosberg H, Muller-Gartner HW. Left-right asymmetry of striatal dopamine D2 receptors. Nucl Med Commun 1998; 19: 781-7.
55. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 2000; 20: 423-51.
56. Lawrence NS, Ross TJ, Hoffmann R, Garavan H, Stein EA. Multiple neuronal networks mediate sustained attention. J Cogn Neurosci 2003; 15: 1028-38.
57. Leo D, Sorrentino E, Volpicelli F, Eyman M, Greco D, Viggiano D, et al. Altered midbrain dopaminergic neurotransmission during development in an animal model of ADHD. Neurosci Biobehav Rev 2003; 27: 661-9.
58. Leyton M, Boileau I, Benkelfat C, Diksic M, Baker G, Dagher A. Amphetamine-induced increases in extracellular dopamine, drug wanting, and novelty seeking: a PET/[11C]raclopride study in healthy men. Neuropsychopharmacology 2002; 27: 1027-35.
59. Li SC, Lindenberger U, Sikstrom S. Aging cognition: from neuromodulation to representation. Trends Cogn Sci 2001; 5: 479-86.
60. MacDonald SW, Cervenka S, Farde L, Nyberg L, Backman L. Extrastriatal dopamine D2 receptor binding modulates intraindividual variability in episodic recognition and executive functioning. Neuropsychologia 2009; 47: 2299-304.
61. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 2003; 23: 285-300.
62. Mattay VS, Callicott JH, Bertolino A, Heaton I, Frank JA, Coppola R, et al. Effects of dextroamphetamine on cognitive performance and cortical activation. Neuroimage 2000; 12: 268-75.
63. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 2003; 100: 6186-91.
64. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 2001; 21: 1034-57.
65. McNicol D. A primer of signal detection theory. London: Allen & Unwin; 1972.
66. Mehta MA, Goodyer IM, Sahakian BJ. Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity. J Child Psychol Psychiatry 2004; 45: 293-305.
67. Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins TW. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci 2000; 20: RC65.
68. Mercuri NB, Calabresi P, Bernardi G. The electrophysiological actions of dopamine and dopaminergic drugs on neurons of the substantia nigra pars compacta and ventral tegmental area. Life Sci 1992; 51: 711-8.
69. Mercuri NB, Saiardi A, Bonci A, Picetti R, Calabresi P, Bernardi G, et al. Loss of autoreceptor function in dopaminergic neurons from dopamine D2 receptor deficient mice. Neuroscience 1997; 79: 323-7.
70. Nakao T, Radua J, Rubia K, Mataix-Cols D. Gray matter volume abnormalities in ADHD: voxel-based meta-Analysis exploring the effects of age and stimulant medication. Am J Psychiatry 2011; 168: 1154-63.
71. Naylor H, Halliday R, Callaway E. The effect of methylphenidate on information processing. Psychopharmacology (Berl) 1985; 86: 90-5.
72. Nelson H. National Adult Reading Test (NART): test manual. Windsor, UK: NFER-Nelson; 1982.
73. Nigg JT. On inhibition/disinhibition in developmental psychopathology: views from cognitive and personality psychology and a working inhibition taxonomy. Psychol Bull 2000; 126: 220-46.
74. Nigg JT. Neuropsychologic theory and findings in attention-deficit/ hyperactivity disorder: the state of the field and salient challenges for the coming decade. Biol Psychiatry 2005; 57: 1424-35.
75. Oades R, Taghzouti K, Simon H, Le Moal M. Dopamine-sensitive alternation and collateral behaviour in a Y-maze: effects of d-Amphetamine and haloperidol. Psychopharmacology (Berl) 1985; 85: 123-8.
76. Paloyelis Y, Mehta MA, Kuntsi J, Asherson P. Functional MRI in ADHD: a systematic literature review. Expert Rev Neurother 2007; 7: 1337-56.
77. Rapoport JL, Buchsbaum MS, Zahn TP, Weingartner H, Ludlow C, Mikkelsen EJ. Dextroamphetamine: cognitive and behavioral effects in normal prepubertal boys. Science 1978; 199: 560-3.
78. Rapoport JL, Buchsbaum MS, Weingartner H, Zahn TP, Ludlow C, Mikkelsen EJ. Dextroamphetamine. Its cognitive and behavioral effects in normal and hyperactive boys and normal men. Arch Gen Psychiatry 1980; 37: 933-43.
79. Riccardi P, Li R, Ansari MS, Zald D, Park S, Dawant B, et al. Amphetamine-induced displacement of [18F] fallypride in striatum and extrastriatal regions in humans. Neuropsychopharmacology 2006a; 31: 1016-26.
80. Riccardi P, Zald D, Li R, Park S, Ansari MS, Dawant B, et al. Sex differences in amphetamine-induced displacement of [(18)F]fallypride in striatal and extrastriatal regions: a PET study. Am J Psychiatry 2006b; 163: 1639-41.
81. Robbins TW. From behavior to cognition: functions of mesostriatal, mesolimbic and mesocortical dopamine systems. In: Iversen LL, Iversen SD, Dunnett SB, Bjorklund A, editors. Dopamine handbook. New York: Oxford University Press; 2010. p. 203-14.
82. Robbins TW, Sahakian BJ. "Paradoxical" effects of psychomotor stimulant drugs in hyperactive children from the standpoint of behavioural pharmacology. Neuropharmacology 1979; 18: 931-50.
83. Rogers RD, Blackshaw AJ, Middleton HC, Matthews K, Hawtin K, Crowley C, et al. Tryptophan depletion impairs stimulus-reward learning while methylphenidate disrupts attentional control in healthy young adults: implications for the monoaminergic basis of impulsive behaviour. Psychopharmacology (Berl) 1999; 146: 482-91.
84. Romanos M, Weise D, Schliesser M, Schecklmann M, Loffler J, Warnke A, et al. Structural abnormality of the substantia nigra in children with attention-deficit hyperactivity disorder. J Psychiatry Neurosci 2010; 35: 55-8.
85. Rosa-Neto P, Lou HC, Cumming P, Pryds O, Karrebaek H, Lunding J, et al. Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity disorder. Neuroimage 2005; 25: 868-76.
86. Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med 1998; 39: 904-11.
87. Sahakian B, Morein-Zamir S. Professor's little helper. Nature 2007; 450: 1157-9.
88. Sahakian BJ, Robbins TW. Are the effects of psychomotor stimulant drugs on hyperactive children really paradoxical? Med Hypotheses 1977; 3: 154-8.
89. Sawaguchi T, Matsumura M, Kubota K. Dopamine enhances the neuronal activity of spatial short-Term memory task in the primate prefrontal cortex. Neurosci Res 1988; 5: 465-73.
90. Schrimsher GW, Billingsley RL, Jackson EF, Moore BD 3rd. Caudate nucleus volume asymmetry predicts attention-deficit hyperactivity disorder (ADHD) symptomatology in children. J Child Neurol 2002; 17: 877-84.
91. Seeman P, Madras BK. Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatry 1998; 3: 386-96.
92. Seidman LJ, Valera EM, Makris N. Structural brain imaging of attentiondeficit/hyperactivity disorder. Biol Psychiatry 2005; 57: 1263-72.
93. Servan-Schreiber D, Bruno RM, Carter CS, Cohen JD. Dopamine and the mechanisms of cognition: Part I. A neural network model predicting dopamine effects on selective attention. Biol Psychiatry 1998; 43: 713-22.
94. Sesack SR, Aoki C, Pickel VM. Ultrastructural localization of D2 receptorlike immunoreactivity in midbrain dopamine neurons and their striatal targets. J Neurosci 1994; 14: 88-106.
95. Sheehan DV, Sheehan KH, Shytle RD, Janavs J, Bannon Y, Rogers JE, et al. Reliability and validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID). J Clin Psychiatry 2010; 71: 313-26.
96. Shi WX, Pun CL, Zhou Y. Psychostimulants induce low-frequency oscillations in the firing activity of dopamine neurons. Neuropsychopharmacology 2004; 29: 2160-7.
97. Simon V, Czobor P, Balint S, Meszaros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-Analysis. Br J Psychiatry 2009; 194: 204-11.
98. Slifstein M, Kegeles LS, Xu X, Thompson JL, Urban N, Castrillon J, et al. Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride. Synapse 2010; 64: 350-62.
99. Solanto MV. Neuropharmacological basis of stimulant drug action in attention deficit disorder with hyperactivity: a review and synthesis. Psychol Bull 1984; 95: 387-409.
100. Solanto MV. Behavioral effects of low-dose methylphenidate in childhood attention deficit disorder: implications for a mechanism of stimulant drug action. J Am Acad Child Psychiatry 1986; 25: 96-101.
101. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998; 94: 127-52.
102. Spencer TJ, Adler LA, McGough JJ, Muniz R, Jiang H, Pestreich L. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2007; 61: 1380-7.
103. Strauss J, Lewis JL, Klorman R, Peloquin LJ, Perlmutter RA, Salzman LF. Effects of methylphenidate on young adults' performance and eventrelated potentials in a vigilance and a paired-Associates learning test. Psychophysiology 1984; 21: 609-21.
104. Tipper CM, Cairo TA, Woodward TS, Phillips AG, Liddle PF, Ngan ET. Processing efficiency of a verbal working memory system is modulated by amphetamine: an fMRI investigation. Psychopharmacology (Berl) 2005; 180: 634-43.
105. Turner DC, Blackwell AD, Dowson JH, McLean A, Sahakian BJ. Neurocognitive effects of methylphenidate in adult attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) 2005; 178: 286-95.
106. Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ. Relative lack of cognitive effects of methylphenidate in elderly male volunteers. Psychopharmacology (Berl) 2003; 168: 455-64.
107. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI singlesubject brain. Neuroimage 2002; 15: 273-89.
108. Vernaleken I, Weibrich C, Siessmeier T, Buchholz HG, Rosch F, Heinz A, et al. Asymmetry in dopamine D(2/3) receptors of caudate nucleus is lost with age. Neuroimage 2007; 34: 870-8.
109. Volkow ND. Stimulant medications: how to minimize their reinforcing effects? Am J Psychiatry 2006; 163: 359-61.
110. Volkow ND. Long-Term safety of stimulant use for ADHD: findings from nonhuman primates. Neuropsychopharmacology 2012; 37: 2551-2.
111. Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH, Telang F, et al. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA 2009; 302: 1084-91.
112. Volkow ND, Wang GJ, Newcorn J, Fowler JS, Telang F, Solanto MV, et al. Brain dopamine transporter levels in treatment and drug naive adults with ADHD. Neuroimage 2007a; 34: 1182-90.
113. Volkow ND, Wang GJ, Newcorn J, Telang F, Solanto MV, Fowler JS, et al. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2007b; 64: 932-40.
114. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995; 376: 572-5.